Abstract:OBJECTIVESTo develop new HIV-1 fusion inhibitors with improved antiviral activities and resistance profiles, we designed two categories of artificial peptides, each containing four heptad repeats (m4HR) conjugated with a pocket-specific small molecule (pssm) or pssm and cholesterol (chol), designated pssm-m4HR or pssm-m4HR-chol, respectively, and tested their anti-HIV-1 activity.METHODSWe synthesized the artificial peptides and conjugated these peptides with pssm and chol using a standard solid-phase Fmoc protocol and a chemoselective thioether conjugation method, respectively. We tested the inhibitory activities of the peptide conjugates against HIV-1 Env-mediated cell-cell fusion and infection by laboratory-adapted and primary HIV-1 isolates, and enfuvirtide-resistant HIV-1 strains using cell-cell fusion and p24 production assays, respectively. We assessed their cytotoxicity towards MT-2 cells using the XTT assay.RESULTSWe found that pssm-m4HR conjugates exhibited promising inhibitory activity against HIV-1 Env-mediated cell-cell fusion and laboratory-adapted HIV-1 replication with IC50 values at the low micromolar level, whereas the pssm-m4HR-chol conjugates exhibited dramatically increased anti-HIV-1 activities with IC50 values at the low nanomolar level. Some of the pssm-m4HR-chol conjugates (e.g. 5a and 5b) showed highly potent antiviral activity against infection by primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains. All the conjugates displayed no or low cytotoxicity towards MT-2 cells. The result of a prime/wash assay indicated pssm-m4HR-chol conjugates were strongly anchored to the membrane and sustained a potent inhibitory effect after washing.CONCLUSIONSThese results suggest this scaffold design is a promising strategy for developing novel peptide conjugates with improved antiviral activity against a broad spectrum of HIV-1 strains, including those highly resistant to enfuvirtide.

Peptides derived from HIV-1 gp120 co-receptor binding domain form amyloid fibrils and enhance HIV-1 infection.

gp120-derived amyloidogenic peptides form amyloid fibrils that increase HIV-1 infectivity

A Peptide Derived from the Hiv-1 Gp120 Coreceptor-Binding Region Promotes Formation of Pap248-286 Amyloid Fibrils to Enhance Hiv-1 Infection

A Degraded Fragment of HIV-1 Gp120 in Rat Hepatocytes Forms Fibrils and Enhances HIV-1 Infection.

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Enhancement of Human Immunodeficiency Virus Type 1 Infection by Antisera to Peptides from the Envelope Glycoproteins Gp120/gp41.

Design, Synthesis and Activity Evaluation of Novel Peptide Fusion Inhibitors Targeting HIV-1 Gp41

Scyllatoxin-based peptide design for E. coli expression and HIV gp120 binding

Design and Biological Evaluation of M-Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 Gp41 Hexameric Coiled-Coil Fusion Complex.

HIV Entry Inhibitors Targeting Gp41: from Polypeptides to Small-Molecule Compounds

Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: The envelope of the human immunodeficiency virus (HIV-1)

Correction: HIV-1 Fusion is Blocked Through Binding of GB Virus C E2D Peptides to the HIV-1 Gp41 Disulfide Loop.

Artificial Peptides Conjugated with Cholesterol and Pocket-Specific Small Molecules Potently Inhibit Infection by Laboratory-Adapted and Primary HIV-1 Isolates and Enfuvirtide-Resistant HIV-1 Strains.

3-Hydroxyphthalic Anhydride- Modified Rabbit Anti-PAP IgG As a Potential Bifunctional HIV-1 Entry Inhibitor

An Amphipathic Peptide Targeting the Gp41 Cytoplasmic Tail Kills HIV-1 Virions and Infected Cells

Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41.

Design of artificial α-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors

An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane

Design of the artificial N-peptides with coiled-coil trimer structure against HIV-1 based on the SWISS MODEL and HDOCK-aided strategy

A Novel Peptide Shows Excellent Anti-Hiv-1 Potency As a Gp41 Fusion Inhibitor

Immunoinformatic Identification of Multiple Epitopes of gp120 Protein of HIV-1 to Enhance the Immune Response against HIV-1 Infection